{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=1&page=84", "query": { "intervention": "1", "page": 84 }, "page_size": 10 }, "pagination": { "page": 84, "page_size": 10, "total_count": 4611, "total_pages": 462, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=1&page=85&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=1&page=83&page_size=10" }, "source": "local", "last_synced_at": "2026-11-03T18:29:16.613Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05302271", "title": "Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cardiac Hypertrophy", "Cardiomyopathies", "Friedreich Ataxia", "Myocardial Fibrosis" ], "interventions": [ { "name": "AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "12 Years to 50 Years" }, "enrollment_count": 25, "start_date": "2022-02-22", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-18T01:31:28.486Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05302271" }, { "nct_id": "NCT07841470", "title": "Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Corneal Ectasia", "Keratoconus" ], "interventions": [ { "name": "Riboflavin 0.1% ophthalmic solution and non-pulsed light", "type": "COMBINATION_PRODUCT" }, { "name": "Riboflavin 0.1% ophthalmic solution and pulsed light", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Price Vision Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "10 Years to 90 Years" }, "enrollment_count": 500, "start_date": "2025-10-01", "completion_date": "2031-06-30", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-16T15:06:50.782Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07841470" }, { "nct_id": "NCT07765706", "title": "A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "INS1033", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Insmed Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 116, "start_date": "2026-08-25", "completion_date": "2027-03-22", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-14T09:09:23.834Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07765706" }, { "nct_id": "NCT07612176", "title": "A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced (Unresectable) or Metastatic Solid Tumors" ], "interventions": [ { "name": "NEOK001", "type": "DRUG" }, { "name": "NEOK001 RDE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NEOK Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2026-04-21", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-06T00:36:21.096Z", "location_count": 9, "location_summary": "New York, New York • Nashville, Tennessee • Austin, Texas + 4 more", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Austin", "state": "Texas" }, { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07612176" }, { "nct_id": "NCT07227818", "title": "Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "NBI-1117568", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neurocrine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 560, "start_date": "2025-12-16", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-13T21:55:53.269Z", "location_count": 22, "location_summary": "Garden Grove, California • La Habra, California • Lemon Grove, California + 17 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "La Habra", "state": "California" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227818" }, { "nct_id": "NCT07174466", "title": "The e-SINCERE Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Digital Health Literacy", "Health Services Utilization", "Social Determinants of Health (SDOH)" ], "interventions": [ { "name": "Standard Referral to 211", "type": "OTHER" }, { "name": "e-SINCERE (Digital Navigation)", "type": "BEHAVIORAL" }, { "name": "e-SINCERE (Phone Support)", "type": "BEHAVIORAL" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "Andrea Wallace", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2025-08-08", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-22T10:55:44.260Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07174466" }, { "nct_id": "NCT07114874", "title": "NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "NBI-1117568", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neurocrine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 600, "start_date": "2025-07-11", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-12T00:21:06.342Z", "location_count": 50, "location_summary": "Bryant, Arkansas • Little Rock, Arkansas • Cerritos, California + 43 more", "locations": [ { "city": "Bryant", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Chino", "state": "California" }, { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07114874" }, { "nct_id": "NCT07105098", "title": "NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "NBI-1117568", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neurocrine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 284, "start_date": "2025-08-11", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-03T00:06:24.410Z", "location_count": 7, "location_summary": "Little Rock, Arkansas • Culver City, California • Garden Grove, California + 4 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Culver City", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07105098" }, { "nct_id": "NCT07073547", "title": "A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "AZD0120", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-07-31", "completion_date": "2028-05-26", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-15T17:34:09.008Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Duarte, California • Denver, Colorado + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07073547" }, { "nct_id": "NCT07007559", "title": "ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer, Metastatic" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Evorpacept (ALX148)", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ALX Oncology Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-12-10", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-11-03T18:29:16.613Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07007559" } ] }